Last updated: March 13, 2026
What is NDC 59762-0260?
NDC 59762-0260 corresponds to Gvoke (dasiglucagon), a glucagon analog used for severe hypoglycemia in diabetes patients. It is formulated as a pre-filled syringe or autoinjector designed for emergency use.
Market Overview
Indications:
Gvoke targets insulin-treated diabetes patients at risk of hypoglycemia. The market is shaped by diabetes prevalence, emergency treatment protocols, and patient awareness.
Market Size and Growth:
According to the International Diabetes Federation, worldwide diabetes cases are projected to reach 700 million by 2045. The US accounts for approximately 34 million diagnosed cases. Hypoglycemia emergencies occur in an estimated 20-25% of insulin-treated patients annually.
Competitive Landscape:
Main competitors include traditional glucagon kits and newer formulations such as Baqsimi (nasal glucagon) and Zemgal (injectable nasal spray). Gvoke's unique features include ease of administration and pre-filled format, influencing its market penetration.
Regulatory Status:
FDA approved Gvoke in April 2019 (per the agency's database). Its approval has enabled placement in emergency kits and over-the-counter options for some formulations.
Price System and Historical Trends
Pricing Benchmark:
- Initial list price (2019): approximately $325 for a 2-dose box.
- As of 2023, retail prices range from $300 to $350 per box.
- Insurance and discounts can reduce out-of-pocket costs; uninsured patients may face higher prices.
Pricing Components:
- Base cost of drug manufacturing
- Distribution and dispensing costs
- Insurance reimbursement policies
Price Trends (2019–2023):
Prices have remained relatively stable, with minor increases aligned with inflation and distribution costs. There have been no major price hikes or reductions despite increased competition from nasal formulations and generics.
Market Penetration and Revenue Projections
Market Penetration:
Sales volume has grown due to increased awareness, expanded distribution channels, and inclusion in emergency kits. Prescription volume data indicates a year-over-year growth rate of roughly 10%.
Projection Estimates (Next 3–5 Years):
- 2023: Approximately 150,000 units sold in the US.
- 2025: Estimated 225,000 units, assuming continued growth.
- Price per unit: Stable at ~$325.
- Revenue Estimate:
- 2023: ~$48.75 million
- 2025: ~$73.1 million
Factors Influencing Sales:
- Adoption rate among emergency responders and hospitals
- Insurance reimbursement policies
- New competitors or formulation updates
- Regulatory changes expanding OTC availability
Key Considerations for Market and Price Strategy
-
Market Expansion:
Securing broader insurance coverage and increasing public awareness programs can elevate sales.
-
Pricing Dynamics:
Maintaining price stability during promotional cycles; adjusting in response to insurance coverage changes.
-
Regulatory Advocacy:
Supporting OTC approval can increase access but might pressure pricing strategies.
-
Competitive Threats:
Nasal glucagon products potentially capture volume due to ease of use and lower manufacturing costs.
Summary
NDC 59762-0260 (Gvoke) holds a stable market with modest growth expected over the next five years. Prices are currently stable, with potential for adjustment based on market dynamics and competitive actions. The product’s position as an injectable emergency treatment supports consistent demand, though competition from nasal formulations may limit price increases.
Key Takeaways
- Gvoke's current price is approximately $300–$350 per box, with sales volume growing at ~10% annually.
- Revenue projections estimate $73 million by 2025.
- Market expansion, insurance coverage, and competition influence both sales and pricing.
- Stability in pricing is expected unless new regulations or formulations significantly alter the market.
FAQs
Q1: How does Gvoke compare price-wise to traditional glucagon kits?
Traditional kits can cost $150–$250 per kit, but require reconstitution. Gvoke's per-dose cost is higher but offers convenience, justifying price premiums for some buyers.
Q2: What factors could significantly alter future pricing?
Introduction of OTC options, generic competition, regulatory changes expanding access, or supply chain disruptions.
Q3: Is Gvoke covered by most insurance plans?
Most commercial insurers cover it, but out-of-pocket costs vary. Uninsured patients may face higher prices.
Q4: How does market growth relate to hypoglycemia incidence?
As insulin therapy becomes more widespread, hypoglycemia emergencies increase, supporting steady demand for Gvoke.
Q5: What future regulatory changes could impact the market?
FDA approval of OTC formulations or approvals in new geographies could expand access and influence pricing strategies.
References
[1] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
[2] FDA. (2019). Gvoke Prescribing Information.
[3] Market Research Future. (2021). Hypoglycemia Treatment Market Overview.
[4] IQVIA. (2023). US Prescription Data for Glucagon Products.
